EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL/RANK/OPG molecular complex--control factors in bone remodeling in psoriatic arthritis



RANKL/RANK/OPG molecular complex--control factors in bone remodeling in psoriatic arthritis



Revista Medico-Chirurgicala A Societatii de Medici Si Naturalisti Din Iasi 115(2): 354-360



To investigate the blood levels of bone remodeling factors (RANKL, OPG and Bone-ALP) in psoriatic arthritis patients. Included in this study were 27 patients with psoriatic arthritis (CASPAR classification criteria) and 20 healthy subjects. The RANKL , OPG and Bone-ALP levels have been quantified by ELISA method. Peripheral blood concentrations were higher in psoriatic arthritis than in the healthy subjects, and a strong negative correlation between RANKL and OPG and between RANKL and Bone-ALP was also found. The increase in OPG and Bone-ALP serum level is strongly related to the increase in RANKL serum level in patients with psoriatic arthritis. The increase in OPG and Bone-ALP serum level induces the production of bone matrix parallel to the bone destruction mediated by RANKL. The follow up of the patients with psoriatic arthritis by early RANKL, OPG and Bone-ALP serum level determinations, and of bone metabolism markers (with specific role in bone remodeling), allows an accurate evaluation of disease activity and, in the future, could be a criterion for the initiation of specific, targeted treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 055333216

Download citation: RISBibTeXText

PMID: 21870723



Related references

Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian Journal of Endocrinology and Metabolism 15(3): 175-181, 2011

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews 15(6): 457-475, 2004

Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives of Biochemistry and Biophysics 473(2): 139-146, 2008

Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Human Genetics 118(5): 568-577, 2005

Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology 262(2): 306-316, 2010

Role of RANKL and RANK in bone loss and arthritis. Annals of the Rheumatic Diseases 61 Suppl 2: Ii32-Ii39, 2002

Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway. Evidence-Based Complementary and Alternative Medicine 2013: 626038-626038, 2013

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14(5): 913-918, 2007

Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways. World Journal of Orthopedics 4(1): 1-6, 2013

Genetic variations in the genes encoding receptor activator nuclear factor κ B (RANK), receptor activator nuclear factor κ B ligand (RANKL) and osteoprotegerin (OPG) in patients with psoriasis and psoriatic arthritis: a case-control study. Journal of Dermatology 38(6): 519-523, 2011

Simulated rates of resorption during cancellous bone remodeling using Michaelis-Menten equations and the interactive effects of RANKL, RANK and OPG on osteoclast activity. Calcified Tissue International 72(4): 363, April, 2003

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. Journal of Clinical Investigation 111(6): 821-831, 2003

Control of bone resorption by RANKL-RANK system. Clinical Calcium 21(8): 1121-1130, 2011

Inhibition of RANKL/RANK signaling as a mechanism of the bone-sparing effects of p38 MAPK inhibitors in rodent arthritis. Journal of Bone & Mineral Research 16(Suppl 1): S385, September, 2001

RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. Advances in Experimental Medicine and Biology 649: 100-113, 2009